The top 10 companies in the French retail generics market for 2024 according to Smart Pharma Consulting’s insights on the French pharma market. Last year, Viatris and Biogaran generated more than EUR 2.9 billion in sales and, taken together, represented over half of the total French retail generic market in terms of value. Made…
France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are the threats to further collaborations in the coming years? For a country with a population of just six million people, Denmark’s life sciences industry…
France finally has a full budget for 2026, ending months of stasis, and providing a degree of certainty to industry. However, especially for pharma, continual price cuts threaten the sustainability of France as an investment destination, although the reindustrialisation incentives contained with the ‘France 2030’ plan are leading to an unprecedented life sciences manufacturing boom.…
Spain Spain: Still Europe’s Top Clinical Trial Destination, EUR 2 Billion Roche Manufacturing Investment, Almirall Looking Up
The latest stories from Spain’s booming healthcare and life science industry. Spain still leads Europe for clinical trial numbers, while a recent meeting between Spanish PM Pedro Sánchez and Roche CEO Thomas Schinecker on a new manufacturing agreement speaks to global pharma’s continued focus on the country. In other news, profits are up at Almirall,…
